Modality
Peptide
MOA
Menini
Target
PARP
Pathway
Innate Imm
ETMCLHNSCC
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
~Feb 2022
→ ~May 2023
NDA/BLA
Aug 2023
→ Jan 2031
NDA/BLACurrent
NCT04054049
1,039 pts·MCL
2023-08→2031-01·Recruiting
1,039 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-174.8y awayPh3 Readout· MCL
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-01-17 · 4.8y away
MCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04054049 | NDA/BLA | MCL | Recruiting | 1039 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |